title: Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.
abstract: BACKGROUND
  The serotonin selective reuptake inhibitors are increasingly being used for the treatment of panic disorder. We examined the efficacy and safety of the serotonin selective reuptake inhibitor sertraline hydrochloride in patients with panic disorder.
  
  
  METHODS
  One hundred seventy-six nondepressed outpatients with panic disorder, with or without agoraphobia, from 10 sites followed identical protocols that used a flexible-dose design. After 2 weeks of single-blind placebo, patients were randomly assigned to 10 weeks of double-blind, flexible-dose treatment with either sertraline hydrochloride (50-200 mg/d) or placebo.
  
  
  RESULTS
  Sertraline-treated patients exhibited significantly greater improvement (P=.01) at end point than did patients treated with placebo for the primary outcome variable, panic attack frequency. Significant differences between groups were also evident for clinician and patient assessments of improvement as measured by the Clinical Global Impression Improvement (P=.01) and Severity (P=.009) Scales, Panic Disorder Severity Scale ratings (P=.03), high end-state function assessment (P=.03), Patient Global Evaluation rating (P=.01), and quality of life scores (P=.003). Adverse events, generally characterized as either mild or moderate, were not significantly different in overall incidence between the sertraline and placebo groups.
  
  
  CONCLUSIONS
  Results support the safety and efficacy of sertraline for the short-term treatment of patients with panic disorder.
authors.affiliation: Anxiety Disorders Program, Department of Psychiatry, Massachusetts General Hospital, Boston 02114-3117, USA. MPollack@Partners.org
authors.forename: M H
authors.initials: MH
authors.lastname: Pollack
authors.forename: M W
authors.initials: MW
authors.lastname: Otto
authors.forename: J J
authors.initials: JJ
authors.lastname: Worthington
authors.forename: G G
authors.initials: GG
authors.lastname: Manfro
authors.forename: R
authors.initials: R
authors.lastname: Wolkow
mesh_terms: D000293:Adolescent; D000328:Adult; D000379:Agoraphobia / Q000188:drug therapy / Q000523:psychology; D000553:Ambulatory Care; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D016584:Panic Disorder / Q000188:drug therapy* / Q000523:psychology; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D020280:Sertraline / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline